Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 779Lung Neoplasms 345Ovarian Neoplasms 323Breast Neoplasms 279Fallopian Tube Neoplasms 159Triple Negative Breast Neoplasms 145Small Cell Lung Carcinoma 144Neoplasms 137Squamous Cell Carcinoma of Head and Neck 123Carcinoma, Ovarian Epithelial 114Neoplasm Metastasis 85Head and Neck Neoplasms 80Endometrial Neoplasms 76Uterine Cervical Neoplasms 72Esophageal Neoplasms 71Adenocarcinoma of Lung 70Neuroblastoma 55Central Nervous System Neoplasms 53Lymphoma, Large B-Cell, Diffuse 49Carcinoma 49Recurrence 48Brain Neoplasms 48Prostatic Neoplasms 44Parkinson Disease 4, Autosomal Dominant Lewy Body 44Urinary Bladder Neoplasms 42Esophageal Squamous Cell Carcinoma 41Lymphoma 39Melanoma 35Carcinoma, Squamous Cell 33Stomach Neoplasms 31

Interventions

pembrolizumab 10Nivolumab 9Ipilimumab 4avelumab 3Neoadjuvant Therapy 3toripalimab 2sintilimab 2durvalumab 2atezolizumab 2Specimen Handling 2Immune Checkpoint Inhibitors 2Celecoxib 2tislelizumab 1spartalizumab 1relatlimab 1regorafenib 1fludarabine phosphate 1fludarabine 1dostarlimab 1denileukin diftitox 1danvatirsen 1camrelizumab 1XELOX 1Taxes 1Surgical Procedures, Operative 1Radiation Dose Hypofractionation 1Paclitaxel 1Oxaliplatin 1Megestrol Acetate 1Medroxyprogesterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Turcot syndrome × Carboplatin × Clear all
NCT04906382 2025-02-13

Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer

Ohio State University Comprehensive Cancer Center

Phase EARLY_PHASE1 Terminated
2 enrolled
GastrointestinalGynecologic

Turcot syndrome, Colorectal Neoplasms, Hereditary Nonpolyposis, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡